JP2021169472A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021169472A5 JP2021169472A5 JP2021111672A JP2021111672A JP2021169472A5 JP 2021169472 A5 JP2021169472 A5 JP 2021169472A5 JP 2021111672 A JP2021111672 A JP 2021111672A JP 2021111672 A JP2021111672 A JP 2021111672A JP 2021169472 A5 JP2021169472 A5 JP 2021169472A5
- Authority
- JP
- Japan
- Prior art keywords
- cebranopadol
- daily dose
- period
- dosing period
- dosing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CSMVOZKEWSOFER-RQNOJGIXSA-N cebranopadol Chemical compound C1([C@]2(CC[C@@]3(CC2)C2=C(C4=CC(F)=CC=C4N2)CCO3)N(C)C)=CC=CC=C1 CSMVOZKEWSOFER-RQNOJGIXSA-N 0.000 claims description 50
- 229950004621 cebranopadol Drugs 0.000 claims description 50
- 208000002193 Pain Diseases 0.000 claims description 8
- 230000002354 daily effect Effects 0.000 claims 50
- 239000003814 drug Substances 0.000 claims 15
- 230000002045 lasting effect Effects 0.000 claims 13
- 229940079593 drug Drugs 0.000 claims 5
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 230000003203 everyday effect Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 230000003040 nociceptive effect Effects 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16157868.7 | 2016-02-29 | ||
| EP16157868 | 2016-02-29 | ||
| EP16020302 | 2016-08-11 | ||
| EP16020302.2 | 2016-08-11 | ||
| JP2018543634A JP7373904B2 (ja) | 2016-02-29 | 2017-02-28 | セブラノパドールの滴定 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543634A Division JP7373904B2 (ja) | 2016-02-29 | 2017-02-28 | セブラノパドールの滴定 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021169472A JP2021169472A (ja) | 2021-10-28 |
| JP2021169472A5 true JP2021169472A5 (https=) | 2022-11-08 |
Family
ID=58185482
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543634A Active JP7373904B2 (ja) | 2016-02-29 | 2017-02-28 | セブラノパドールの滴定 |
| JP2021111672A Pending JP2021169472A (ja) | 2016-02-29 | 2021-07-05 | セブラノパドールの滴定 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543634A Active JP7373904B2 (ja) | 2016-02-29 | 2017-02-28 | セブラノパドールの滴定 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11229625B2 (https=) |
| EP (1) | EP3423054A1 (https=) |
| JP (2) | JP7373904B2 (https=) |
| CN (2) | CN118286209A (https=) |
| AU (1) | AU2017226830B2 (https=) |
| BR (1) | BR112018017167A2 (https=) |
| CA (1) | CA3015420C (https=) |
| IL (1) | IL261133A (https=) |
| MX (1) | MX2018010367A (https=) |
| WO (1) | WO2017148595A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7373904B2 (ja) | 2016-02-29 | 2023-11-06 | パーク・セラピューティクス・インコーポレイテッド | セブラノパドールの滴定 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000025769A1 (en) * | 1998-11-02 | 2000-05-11 | Ortho-Mcneil Pharmaceutical, Inc. | Analgesic regimen |
| US6339105B1 (en) | 1999-10-12 | 2002-01-15 | Ortho-Mcneil Pharmaceutical, Inc. | Analgesic regimen |
| DE10252667A1 (de) | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| AU2003297073A1 (en) | 2002-12-13 | 2004-07-09 | Euro-Celtique S.A. | Transdermal buprenorphine dosage regimen for analgesia |
| US7413749B2 (en) | 2003-03-11 | 2008-08-19 | Purdue Pharma L.P. | Titration dosing regimen for controlled release tramadol |
| DE102006046745A1 (de) | 2006-09-29 | 2008-04-03 | Grünenthal GmbH | Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz |
| EP1985292A1 (en) | 2007-04-23 | 2008-10-29 | Grünenthal GmbH | Titration of tapentadol |
| PE20131096A1 (es) | 2010-08-04 | 2013-10-10 | Gruenenthal Chemie | Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil-o n,n-dimetil)-4-fenil-4',9-dihidro-3'h-espiro[ciclohxan-1,1'-pirano[3,4,b]indol]-4-amina para el tratamiento de dolor neuropatico |
| DK2600846T3 (en) | 2010-08-04 | 2016-01-11 | Gruenenthal Gmbh | PHARMACEUTICAL DOSAGE FORM COMPRISING 6'-fluoro- (N-methyl or N, N-dimethyl -) - 4-phenyl-4 ', 9'-dihydro-3'H-spiro [cyclohexane-1,1'-pyrano [3 , 4, b] indole] -4-amine |
| RS54438B1 (sr) | 2010-08-04 | 2016-06-30 | Grünenthal GmbH | Farmaceutski dozni oblik koji sadrži 6`-fluoro-(n-metil-ili n,n-dimetil-)-4-fenil-4`,9`-dihidro-3`h-spiro[cikloheksan-1,1`-pirano[3,4,b]indol]-4-amina |
| NZ604735A (en) | 2010-08-04 | 2014-08-29 | Gruenenthal Gmbh | Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine |
| PL2649044T3 (pl) | 2010-12-08 | 2018-02-28 | Grünenthal GmbH | Sposób syntezy podstawionych pochodnych aminocykloheksanonu |
| CN106939005A (zh) | 2011-07-08 | 2017-07-11 | 格吕伦塔尔有限公司 | 晶态的（1r,4r）‑6’‑氟‑N,N‑二甲基‑4‑苯基‑4’,9’‑二氢‑3’H‑螺[环己烷‑1,1’‑吡喃并[3,4,b]吲哚]‑4‑胺 |
| US8614245B2 (en) | 2011-07-08 | 2013-12-24 | Gruenenthal Gmbh | Crystalline (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine |
| ES2577861T3 (es) | 2011-12-12 | 2016-07-19 | Grünenthal GmbH | Proceso para la preparación de (1R,4R)-6'-fluor-(N,N-dimetil- y N-metil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano-[3,4,b]indol]-4-amina |
| US8912343B2 (en) | 2011-12-12 | 2014-12-16 | Gruenenthal Gmbh | Solid forms of (1r,4r)-6′-fluoro-(N, N-dimethyl)-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and sulfuric acid |
| MX353331B (es) | 2011-12-12 | 2018-01-09 | Gruenenthal Gmbh | Formas solidas de clorhidrato de (1r,4r)-6´-fluoro-n,n-dimetil-4-f enil-4´,9´-dihidro-3´h-espiro-[ciclohexano-1,1´-pirano[3,4,b]indo l]-4-amina. |
| US8912226B2 (en) | 2012-05-18 | 2014-12-16 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR |
| US9308196B2 (en) | 2012-05-18 | 2016-04-12 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam |
| US9320729B2 (en) | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative |
| US20130310435A1 (en) | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol |
| US9320725B2 (en) | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid |
| HUE040039T2 (hu) | 2014-02-27 | 2019-02-28 | Gruenenthal Gmbh | Az 5-fluor-triptofol elõállítására szolgáló eljárás |
| CA2974578C (en) | 2015-01-23 | 2020-11-17 | Grunenthal Gmbh | Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function |
| JP7373904B2 (ja) | 2016-02-29 | 2023-11-06 | パーク・セラピューティクス・インコーポレイテッド | セブラノパドールの滴定 |
-
2017
- 2017-02-28 JP JP2018543634A patent/JP7373904B2/ja active Active
- 2017-02-28 MX MX2018010367A patent/MX2018010367A/es unknown
- 2017-02-28 CN CN202410387184.5A patent/CN118286209A/zh active Pending
- 2017-02-28 WO PCT/EP2017/025034 patent/WO2017148595A1/en not_active Ceased
- 2017-02-28 BR BR112018017167A patent/BR112018017167A2/pt not_active IP Right Cessation
- 2017-02-28 EP EP17707471.3A patent/EP3423054A1/en not_active Withdrawn
- 2017-02-28 CN CN201780013921.3A patent/CN109069483A/zh active Pending
- 2017-02-28 CA CA3015420A patent/CA3015420C/en active Active
- 2017-02-28 AU AU2017226830A patent/AU2017226830B2/en not_active Expired - Fee Related
-
2018
- 2018-08-13 IL IL261133A patent/IL261133A/en unknown
- 2018-08-29 US US16/116,055 patent/US11229625B2/en active Active
-
2021
- 2021-07-05 JP JP2021111672A patent/JP2021169472A/ja active Pending
- 2021-12-21 US US17/557,987 patent/US12161627B2/en active Active
-
2024
- 2024-10-31 US US18/933,387 patent/US20250255849A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010525050A5 (https=) | ||
| JP2018514534A5 (https=) | ||
| IL294736A (en) | Preparations including 15-hydroxy-eicosapentaenoic acid and methods of using them | |
| AU2009304002B2 (en) | A medicinal product and treatment | |
| JP2025148449A5 (https=) | ||
| JP2016505050A5 (https=) | ||
| IL307751B1 (en) | Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab | |
| JP2021169472A5 (https=) | ||
| JP2009545546A (ja) | リウマチ性疾患の遅延放出型グルココルチコイド治療 | |
| JP2022177119A5 (https=) | ||
| JP2019535830A5 (https=) | ||
| Dotevall et al. | Controlled clinical trial of mepiprazole in irritable bowel syndrome | |
| CN102813924B (zh) | 一种基于青藤碱的用于镇痛的药物组合产品 | |
| JP2019178177A5 (https=) | ||
| JPWO2022125598A5 (https=) | ||
| CN104906501A (zh) | 治疗银屑病的中药组分组合物 | |
| Giovannoni et al. | 151. Safety and Efficacy of Frexalimab in the Treatment of Relapsing Multiple Sclerosis: 18-month Results from the Phase 2 Open-Label Extension | |
| JPWO2022064387A5 (https=) | ||
| US20190381034A1 (en) | Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases | |
| JPWO2023009425A5 (https=) | ||
| US20160263029A1 (en) | Topical pharmaceutical gel composition of diclofenac sodium | |
| Frankhof | Controlled-release naproxen compared with isoxicam in patients with osteoarthritis | |
| US20160263065A1 (en) | Topical pharmaceutical gel composition of diclofenac sodium | |
| KR20250105657A (ko) | 카피바설팁과 베네토클락스의 치료적 조합 | |
| KR20130036990A (ko) | 통증완화의 효과가 있는 약학적 조성물 |